TRIGLIDE adverse reactions: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Fenofibrate}} {{CMG}}; {{AE}} {{SS}} ==Adverse Reactions== ===Clinical Trials Experience=== Because clinical studies are conducted under widely varying conditio...")
 
(Redirected page to Fenofibrate)
 
Line 1: Line 1:
__NOTOC__
#REDIRECT [[Fenofibrate]]
{{Fenofibrate}}
{{CMG}}; {{AE}} {{SS}}
 
==Adverse Reactions==
 
===Clinical Trials Experience===
 
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect rates observed in clinical practice.
 
Adverse events reported by 2% or more of patients treated with fenofibrate and greater than placebo during double-blind, placebo-controlled trials, regardless of causality, are listed in Table 1. Adverse reactions led to discontinuation of treatment in 5.0% of patients treated with fenofibrate and in 3.0% treated with placebo. Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.
 
{|
|[[File:Fenofibrate01.jpg|thumb|800px]]
|}
 
 
===Postmarketing Experience===
 
The following adverse reactions have been identified during post approval use of fenofibrate:[[ myalgia]], [[rhabdomyolysis]], [[pancreatitis]], [[renal failure]], [[muscle spasms]],[[ acute renal failure], [[hepatitis]], [[cirrhosis]], [[anemia]], [[arthralgia]], [[asthenia]] and severely depressed HDL-cholesterol levels. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a casual relationship to drug exposure.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = TRIGLIDE (FENOFIBRATE) TABLET [SHIONOGI INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=94a4a99b-24df-4e81-b409-5325d36647d2#nlm34067-9 | publisher =  | date =  | accessdate = 12 February 2014 }}</ref>
==References==
 
{{Reflist|2}}
 
{{Lipid modifying agents}}
{{Antigout preparations}}
 
[[Category:Fibrates]]
[[Category:Prodrugs]]
[[Category:Organochlorides]]
[[Category:Benzophenones]]
[[Category:Phenol ethers]]
[[Category:Carboxylate esters]]

Latest revision as of 14:29, 21 July 2014

Redirect to: